Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Home Newsfeeds Guggenheim Downgrades Albireo Pharma to Neutral

Guggenheim Downgrades Albireo Pharma to Neutral

Guggenheim analyst Seamus Fernandez downgrades Albireo Pharma (NASDAQ:ALBO) from Buy to Neutral.

byBenzinga Newsdesk

January 11, 2023

1 minute read

Guggenheim analyst Seamus Fernandez downgrades Albireo Pharma (NASDAQ:ALBO) from Buy to Neutral.

News

Wall Street Journal Reported Sunday Goldman Sachs to Merge Investment Banking, Trading Businesses

By Charles Gross

October 17, 4:42 AM

https://www.wsj.com/articles/goldman-plans-sweeping-reorganization-combining-investment-banking-and-trading-11665973368

TotalEnergies’ Windfall: $689M Seagreen Stake Sale Ignites Renewables Partnership In Thailand

By Lekha Gupta

December 22, 7:38 AM

TotalEnergies SE (NYSE: TTE) penned a deal with the national oil and gas company PTTEP in Thailand for

LYB

Analyst Ratings

17 Analysts Have This to Say About Old Dominion Freight Line

By Benzinga Insights

June 28, 8:01 AM

Over the past 3 months, 17 analysts have published their opinion on Old Dominion Freight Line (NASDAQ:ODFL) stock.…

ODFL

Louisiana-Pacific Q3 Earnings Exceed Expectations

By Shivani Kumaresan

November 1, 11:59 AM

Louisiana-Pacific Corp (NYSE:LPX) reported a third-quarter FY22 sales decline of 16% year-on-year to $852.00 million, beating the consensus of $840.01 million.…

LPX

Guggenheim Downgrades Albireo Pharma to Neutral

Related Posts

Wall Street Journal Reported Sunday Goldman Sachs to Merge Investment Banking, Trading Businesses

TotalEnergies’ Windfall: $689M Seagreen Stake Sale Ignites Renewables Partnership In Thailand

17 Analysts Have This to Say About Old Dominion Freight Line

Louisiana-Pacific Q3 Earnings Exceed Expectations